Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash. It also develops biomarker-targeted antibody therapies for patients with cancer and other diseases comprising DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which has completed Phase 2 study for the treatment of colorectal cancer; and FL-501, a monoclonal antibody inhibiting the GDF-15 protein, which is in preclinical development to treat cancer cachexia, hyperemesis gravidarum and pregnancy-related nausea and vomiting, and other diseases associated with aging and frailty. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. Cypherpunk Technologies Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.…
Cypherpunk Technologies Inc. Q3 2026 Earnings Call Summary
Cypherpunk Technologies (NASDAQ: CYPH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Asset Management industry, part of the Financial Services sector, and reports about 6 employees.
The shares were at 1.410 USD on 20 November 2026, up 207.9% over 52 weeks. Its 52-week range is 0.4130 USD to 4.190 USD: the price is 66.3% below the high and 241.4% above the low.
Its market capitalisation is 210.15M USD.
Cypherpunk Technologies reports return on equity of 3.1% and an operating margin of -122.7%.
It holds more cash than debt, a net cash position of 55.95M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 5.000 USD is 254.6% above the current price. The next earnings report is expected on 15 March 2027.